Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNguyen, Mike-
dc.contributor.authorSegelov, Eva-
dc.contributor.authorGoldstein, David-
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorShapiro, Jeremy-
dc.contributor.authorPrice, Timothy J-
dc.contributor.authorNagrial, Adnan-
dc.contributor.authorChantrill, Lorraine-
dc.contributor.authorLeong, Trevor-
dc.contributor.authorChen, John-
dc.contributor.authorBurge, Matt-
dc.contributor.authorKarapetis, Christos S-
dc.contributor.authorChau, Ian-
dc.contributor.authorLordick, Florian-
dc.contributor.authorRenouf, Daniel-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorRoy, Amitesh C-
dc.identifier.citationExpert Review of Anticancer Therapy 2021; online first: 5 Novemberen
dc.description.abstractPancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localised and advanced pancreatic cancer and offers an expert opinion on current best practice. For patients with localised disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resectable, borderline resectable and locally advanced disease. Advances in metastatic disease are discussed including cytotoxic chemotherapy, targeted therapies and the role of genomic testing to identify patients with molecular alterations. Reviewed literature included; journal publications, abstracts presented at major international oncology meetings and ongoing clinical trials databases. Pancreatic cancer is a devastating diagnosis and despite recent advances has a very poor prognosis. Only a minority of patients, 20%, are diagnosed with potentially curable disease. The shifting paradigm towards neoadjuvant therapy may improve resectability and survival rates however robust evidence is required. Thus far, there has only been limited progress in advanced stage disease. Genomic testing may potentially identify more treatment targets although limited to small subgroups.en
dc.titleUpdate on optimal management for pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert Review of Anticancer Therapyen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.affiliationDepartment of Medical Oncology, School of Clinical Sciences, Monash University and Monash Health, Melbourne 3800, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney 2065, Australiaen
dc.identifier.affiliationCabrini Health, Monash University, Melbourne, Australiaen
dc.identifier.affiliationThe Queen Elizabeth Hospital/University of Adelaide, Adelaide, Australiaen
dc.identifier.affiliationDivision of Radiation Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationFlinders Centre For Innovation in Cancer/ Flinders University, Bedford Park, South Australia, 5042, Australiaen
dc.identifier.affiliationDept. of Medical Oncology, Prince of Wales Hospital, University of NSWen
dc.identifier.affiliationDept. of Medical Oncology, Westmead & Blacktown Hospitals. University of Sydney, NSWen
dc.identifier.affiliationDepartment Medical Oncology, Wollongong Hospital, Illawarra Shoalhaven Local Health District. NSWen
dc.identifier.affiliationDepartment of Cancer Care Services, Royal Brisbane Hospital, University of Queensland, Herston, Queenslanden
dc.identifier.affiliationDept. of Medicine, Royal Marsden Hospital, Institute of Cancer Research, Surrey, London, UKen
dc.identifier.affiliationUniversity Cancer Center Leipzig and Department of Oncology, Gastroenterology, Hepatology, Pneumology and Infectious Diseases, Leipzig University Medical Center, Leipzig, Germanyen
dc.identifier.affiliationDept. of Medical Oncology, BC Cancer. Faculty of Medicine, University of British Columbiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.pubmedid34739362-, Mike
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- Imaging and Therapy- Oncology- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Oct 2, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.